![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
GA Hazelton, JJ Hjelle and CD Klaassen
The effects of three cysteine pro-drugs on the hepatotoxicity and biotransformation of acetaminophen were examined to evaluate the factors responsible for antidotal effectiveness. N-Acetyl-L-cysteine, L- 2-oxothiazolidine-4-carboxylate or the L- or D-isomers of 2- methylthiazolidine-4-carboxylate were administered to male mice immediately after a hepatotoxic dosage of acetaminophen (5.0 mmol/kg). In general the antidotal efficacies and potencies of the L-cysteine pro- drugs were similar; 5.0 mmol/kg prevented hepatotoxicity whereas moderate and no protection were observed after 1.65 and 0.55 mmol/kg, respectively. In contrast, the D-isomer of 2-methylthiazolidine-4- carboxylate was ineffective at all dosages. Both L-2-oxothiazolidine-4- carboxylate and L-2-methylthiazolidine-4-carboxylate enhanced blood acetaminophen elimination (28-31% decrease in half-life) whereas N- acetyl-L-cysteine and D-2-methylthiazolidine-4-carboxylate did not. The L-cysteine pro-drugs increased the urinary excretion of the cysteine and mercapturic acid conjugates of acetaminophen (34-119%) but did not alter excretion of acetaminophen-glucuronide or acetaminophen-sulfate. The D-cysteine pro-drug did not affect the urinary excretion of the acetaminophen metabolites examined. Biochemical analyses of the phase II pathway co-substrates, i.e., UDP-glucuronic acid, adenosine 3'- phospho-5'-phosphosulfate and glutathione, were performed on liver samples from mice treated with pro-drugs and/or acetaminophen. The pro- drugs exhibited their greatest effect on hepatic glutathione concentrations. Treatment with L-cysteine pro-drugs decreased the extent of depletion and/or increased the rate of repletion of hepatic glutathione levels after acetaminophen administration.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  S. K. Niture, C. S. Velu, Q. R. Smith, G.J. Bhat, and K. S. Srivenugopal Increased expression of the MGMT repair protein mediated by cysteine prodrugs and chemopreventative natural products in human lymphocytes and tumor cell lines Carcinogenesis, February 1, 2007; 28(2): 378 - 389. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Lee, S. R. Kim, S. J. Park, K. H. Min, K. Y. Lee, S. M. Jin, W. H. Yoo, and Y. C. Lee Antioxidant Down-Regulates Interleukin-18 Expression in Asthma Mol. Pharmacol., October 1, 2006; 70(4): 1184 - 1193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. P. Wallace, S. A. Center, F. H. Hickford, K. L. Warner, and S. Smith S-Adenosyl-L-Methionine (SAMe) for the Treatment of Acetaminophen Toxicity in a Dog J. Am. Anim. Hosp. Assoc., May 1, 2002; 38(3): 246 - 254. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Weiss, S. Heydrick, Y.-Y. Zhang, C. Bierl, A. Cap, and J. Loscalzo Cellular Redox State and Endothelial Dysfunction in Mildly Hyperhomocysteinemic Cystathionine {beta}-Synthase-Deficient Mice Arterioscler. Thromb. Vasc. Biol., January 1, 2002; 22(1): 34 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B L Bartnik, B H. Juurlink, and R M Devon Macrophages: their myelinotrophic or neurotoxic actions depend upon tissue oxidative stress Multiple Sclerosis, February 1, 2000; 6(1): 37 - 42. [Abstract] [PDF]
|
|
|
|
 |
|
 M. A. Levy, B. Sikorski, and T. M. Bray Selective Elevation of Glutathione Levels in Target Tissues with L-2-Oxothiazolidine-4-Carboxylate (OTC) Protects against Hyperoxia-Induced Lung Damage in Protein-Energy Malnourished Rats: Implications for a New Treatment Strategy J. Nutr., April 1, 1998; 128(4): 671 - 676. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
